Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Patterns of adherence behaviour for patients with glaucoma.

Cate H, Bhattacharya D, Clark A, Holland R, Broadway DC.

Eye (Lond). 2013 Apr;27(4):545-53. doi: 10.1038/eye.2012.294. Epub 2013 Jan 18.

PMID:
23328800
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid.

Ajit RR, Fenerty CH, Henson DB.

Eye (Lond). 2010 Aug;24(8):1338-43. doi: 10.1038/eye.2010.27. Epub 2010 Mar 26.

PMID:
20339390
[PubMed - indexed for MEDLINE]
3.

Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.

Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DS.

Ophthalmology. 2009 Feb;116(2):191-9. doi: 10.1016/j.ophtha.2008.09.004. Epub 2008 Dec 12.

PMID:
19084273
[PubMed - indexed for MEDLINE]
4.

Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.

Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Quigley HA.

Ophthalmology. 2009 Jun;116(6):1097-105. doi: 10.1016/j.ophtha.2009.01.021. Epub 2009 Apr 19.

PMID:
19376591
[PubMed - indexed for MEDLINE]
5.

Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination.

Rossi GC, Pasinetti GM, Scudeller L, Tinelli C, Milano G, Bianchi PE.

Expert Opin Pharmacother. 2010 Mar;11(4):499-504. doi: 10.1517/14656561003601994.

PMID:
20163264
[PubMed - indexed for MEDLINE]
6.

Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management.

Cate H, Bhattacharya D, Clark A, Fordham R, Notley C, Broadway DC.

BMC Ophthalmol. 2012 Nov 22;12:57. doi: 10.1186/1471-2415-12-57.

PMID:
23171166
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy.

Fain JM, Kotak S, Mardekian J, Bacharach J, Edward DP, Rauchman S, Brevetti T, Fox JL, Lovelace C.

BMC Ophthalmol. 2011 Jun 13;11:13. doi: 10.1186/1471-2415-11-13.

PMID:
21668980
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma.

Holló G, Kóthy P, Géczy A, Vargha P.

J Glaucoma. 2009 Apr-May;18(4):288-92. doi: 10.1097/IJG.0b013e31818456b9.

PMID:
19365193
[PubMed - indexed for MEDLINE]
9.

Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.

Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S; Travatan Dosing Aid Study Group.

Clin Ther. 2006 Nov;28(11):1803-11.

PMID:
17213000
[PubMed - indexed for MEDLINE]
10.

Do adherence rates and glaucomatous visual field progression correlate?

Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE.

Eur J Ophthalmol. 2011 Jul-Aug;21(4):410-4. doi: 10.5301/EJO.2010.6112.

PMID:
21140373
[PubMed - indexed for MEDLINE]
11.

Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients.

Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DS.

Ophthalmology. 2009 Dec;116(12):2286-93. doi: 10.1016/j.ophtha.2009.05.026. Epub 2009 Oct 7.

PMID:
19815286
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.

Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J.

Clin Ther. 2004 Jan;26(1):84-91.

PMID:
14996520
[PubMed - indexed for MEDLINE]
13.

Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian population-based analysis.

Iskedjian M, Covert DW, Walker JH.

Patient. 2011;4(2):133-41. doi: 10.2165/11539460-000000000-00000.

PMID:
21766903
[PubMed - indexed for MEDLINE]
14.

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group.

Am J Ophthalmol. 2001 Oct;132(4):472-84.

PMID:
11589866
[PubMed - indexed for MEDLINE]
15.

Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.

Chiselită D; Pentru Eastern European Start Study Group.

Oftalmologia. 2007;51(2):81-6.

PMID:
17937041
[PubMed - indexed for MEDLINE]
16.

Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.

Schwartz GF, Tan J, Kotak S.

J Ocul Pharmacol Ther. 2009 Dec;25(6):555-61. doi: 10.1089/jop.2009.0057.

PMID:
20028264
[PubMed - indexed for MEDLINE]
17.

Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.

Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA.

J Ocul Pharmacol Ther. 2010 Jun;26(3):287-92.

PMID:
20578283
[PubMed - indexed for MEDLINE]
18.

Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.

Hahn SR, Kotak S, Tan J, Kim E.

Curr Med Res Opin. 2010 Apr;26(4):957-63. doi: 10.1185/03007991003659012.

PMID:
20163296
[PubMed - indexed for MEDLINE]
19.

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Payet S, Denis P, Berdeaux G, Launois R.

Clin Drug Investig. 2008;28(3):183-98.

PMID:
18266403
[PubMed - indexed for MEDLINE]
20.

Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.

Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S.

Surv Ophthalmol. 2004 Mar;49 Suppl 1:S12-8.

PMID:
15016557
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk